Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD
TruDiagnostic Discount Link (Epigenetic Testing)
CONQUERAGING!
https://bit.ly/3Rken0n.
Age-related macular degeneration (AMD) is the most common cause of vision loss among people aged 50 and older, affecting an estimated 7.3 million individuals in the United States. Of these patients, 1.75 million have advanced AMD and will lose vision from this condition. This includes patients with the “wet” form of AMD, characterized by the growth of abnormal blood vessels in the retina that can bleed or leak damaging fluids into the central portion of this light-sensing tissue.
“Our goal is to re-regulate all of your genes back to an earlier state.” Excellent. Hurry please. I’m 51.
Magnesium Break Through 10% Discount https://bit.ly/3O5tPfu.
This video brought to you by BiOptimizers.
One of the world’s leading hospitals is preparing to offer longevity clinical services to patients. Sheba Medical Center in Tel Aviv, Israel, is poised to open a dedicated longevity centre in 2023, with the goal of democratising the extension of healthy lifespan for the masses.
Longevity. Technology: While research, development and investment in longevity are at an all-time high, the implementation of longevity clinical practice in mainstream healthcare is virtually non-existent. While private clinical practices are now making longevity services accessible to those who can afford it, the societal benefit of improving healthspan can only be realised if everyone can access it. To learn more, we caught up with Professor Tzipi Strauss, Director of Neonatology at Sheba Hospital, who is the driving force behind the new centre.
It may seem curious that a paediatrician is the instigator of an initiative focused on improving aging, but Strauss explains that the relevance of longevity begins at birth.
Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, has launched with the completion of a $96 million Series A financing.
The financing was led by The Column Group and Lux Capital, with additional participation from Two Sigma Ventures, Evotec, Bristol Myers Squibb, Alexandria Venture Investments, Dolby Family Ventures and other investors.
Longevity. Technology: Seattle-based Cajal is committed to discovering novel therapeutics for neurodegeneration; by focusing on the mechanistic, spatial and temporal complexity of neurodegeneration, the biotech’s powerful platform is designed to unlock the complexity of disease at unprecedented scale, and integrates expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput functional validation.
Cardiac alterations in structure and function, namely, the left ventricle, have been intensely studied for decades, in association with aging. In recent times, there has been keen interest in describing myocardial changes that accompany skeletal muscle changes in older adults. Initially described as a cardio-sarcopenia syndrome where alterations in myocardial structure were observed particularly among older adults with skeletal muscle sarcopenia, investigations into this syndrome have spurred a fresh level of interest in the cardiac-skeletal muscle axis. The purpose of this perspective is to summarize the background for this “syndrome of concern,” review the body of work generated by various human aging cohorts, and to explore future directions and opportunities for understanding this syndrome.
The traditional view of cardiovascular aging is that of age-related adaptations in the heart characterized by increased left ventricular (LV) mass (LVM) and LV hypertrophy (LVH), which are often secondary to increased systolic blood pressure mainly mediated by arterial stiffening (1, 2). These changes accumulate throughout the lifetime of an individual, increasing the risk of developing cardiovascular disease (CVD), such as heart failure (HF) and coronary artery disease. The incidence of CVD increases with age, rising from ∼78% among adults aged 60–79 years to ∼90% in those aged above 80 years. CVD is the leading cause of disease burden in the world, with global prevalence doubling from 271 million to 523 million between 1990 and 2019. Incident CVD mortality increased from 12.1 million to 18.6 million in the same period , and accounted for 32% of all deaths. With rapidly aging national populations, these numbers are expected to increase.
Steven Parton [00:00:37] Hello everyone. My name is Steven Parton and you are listening to the feedback loop on Singularity Radio. This week our guest is business and technology reporter Peter Ward. Earlier this year, Peter released his book The Price of Immortality The Race to Live Forever, where he investigates the many movements and organizations that are seeking to increase the human lifespan from the Church of Perpetual Life in Florida to some of the biggest tech giants in Silicon Valley. In this episode, we explore Peter’s findings, which takes us on a tour from cryogenics to mind uploading from supplements to gene editing and much more. Along the way, we discuss the details of how one might actually achieve immortality, talking about senescent cells and telomeres. Discussing whether it’s better to live healthy than to live long. We also discuss the scams and failures that seem to dominate the longevity space, as well as the efforts that seem the most promising. And now, since we’re on the topic of discussing how precious life is, are waste no more of your precious time? So everyone, please welcome to the feedback loop. Peter Ward. Well then, Peter, thanks for joining me. I think the best place to start is in April of this year. You released a book called The Price of Immortality The Race to Live Forever and where I love to start with anyone who’s written a book is just hearing about your motivations for the book. Why did you decide that this was a topic worth exploring?
Dreaming about Immortality has a long history, almost as long as the failed quests to achieve it. And during all these years and years, the solutions for achieving immortality can fall in several categories. The first is to take some kind of “magic pill” – be it the fountain of youth, the elixir of life, the holy grail, till modern medicine of genetic engineering. After the magic “pills” proved to be a failure, the second attempt was through more creative endeavours, such as building a monastery, a temple, making a sculpture or painting, till nowadays when we talk about digital immortality and I guess soon about virtual immortality. And, of course, there were always the “party-spoilers”, the ones asking: why to be Immortal?
Humanity has changed in many ways, but the hope of the dream of Immortality remained and generation after generation, trying to find it in different ways or forms. So, keep with us as we travel alongside the deepest human dream, to see all (the failed) trials.
New work from Gero, conducted in collaboration with researchers from Roswell Park Comprehensive Cancer Center and Genome Protection Inc. and published in Nature Communications, demonstrates the power of AI combined with analytical tools borrowed from the physics of complex systems to provide insights into the nature of aging, resilience and future medical interventions for age-related diseases including cancer.
Longevity. Technology: Modern AI systems exhibit superhuman-level performance in medical diagnostics applications, such as identifying cancer on MRI scans. This time, the researchers took one step further and used AI to figure out principles that describe how the biological process of aging unfolds in time.
The researchers trained an AI algorithm on a large dataset composed of multiple blood tests taken along the life course of tens of thousands of aging mice to predict the future health state of an animal from its current state. The artificial neural network precisely projected the health condition of an aging mouse with the help of a single variable, which was termed dynamic frailty indicator (dFI) that accurately characterises the damage that an animal accumulates throughout life [1].
As any weekend warrior understands, cartilage injuries to joints such as knees, shoulders, and hips can prove extremely painful and debilitating. In addition, conditions that cause cartilage degeneration, like arthritis and temporomandibular joint disorder (TMJ), affect 350 million people in the world and cost the U.S. public health system more than $303 billion every year. Patients suffering from these conditions experience increased pain and discomfort over time.
However, an exciting study led by faculty at The Forsyth Institute suggests new strategies for making cartilage cells with huge implications in regenerative medicine for future cartilage injuries and degeneration treatments. In a paper, entitled “GATA3 mediates nonclassical β-catenin signaling in skeletal cell fate determination and ectopic chondrogenesis,” co-first authors Takamitsu Maruyama and Daigaku Hasegawa, and senior author Wei Hsu, describe two breakthrough discoveries, including a new understanding of a multifaced protein called β-catenin.
Dr. Hsu is a senior scientist at the Forsyth Insitute and a Professor of Developmental Biology at Harvard University. He is also an affiliate faculty member of the Harvard Stem Cell Institute. Other members conducting the study included Swiss scientists Tomas Valenta and Konrad Basler, and Canadian scientists Jody Haigh and Maxime Bouchard. The study appears in the most recent issue of Science Advances.
